Table 2.

Outcomes at 8 years actuarial, comparing the 3 postremission regimens from CCG-2891

Allogeneic BMTAutologous BMTChemotherapy
P value
(allo vs auto)		P value
(auto vs chemo)		Pvalue
(chemo vs allo)
All patients (n = 537) 181  177  179  
Survival 60% ± 9% .002 48% ± 8% .21 53% ± 8% .05 
Disease-free survival 55% ± 9% .001 42% ± 8% .31 47% ± 8% .01 
Patients receiving intensive-timing induction
(n = 336) 		113  115  108  
Survival 70% ± 9% .006 54% ± 9% .67 57% ± 10% .02 
Disease-free survival 66% ± 9% .003 48% ± 9% .53 53% ± 10% .02 
Allogeneic BMTAutologous BMTChemotherapy
P value
(allo vs auto)		P value
(auto vs chemo)		Pvalue
(chemo vs allo)
All patients (n = 537) 181  177  179  
Survival 60% ± 9% .002 48% ± 8% .21 53% ± 8% .05 
Disease-free survival 55% ± 9% .001 42% ± 8% .31 47% ± 8% .01 
Patients receiving intensive-timing induction
(n = 336) 		113  115  108  
Survival 70% ± 9% .006 54% ± 9% .67 57% ± 10% .02 
Disease-free survival 66% ± 9% .003 48% ± 9% .53 53% ± 10% .02 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal